EyeCool Therapeutics Appoints Vance Thompson, MD, to Its Board of Directors

EyeCool Therapeutics has appointed Vance Thompson, MD, to its board of directors. Dr. Thompson is a globally recognized ophthalmologist and founder of Vance Thompson Vision. 

Dr. Thompson brings decades of surgical and research expertise to EyeCool. He has served as principal investigator in over 100 FDA-monitored ophthalmology clinical trials, advancing treatments and technologies for anterior eye disease. He is the immediate past president of the American Society of Cataract and Refractive Surgery (ASCRS) and has performed more than 100,000 vision correction surgeries during his career.

“I am honored to join the board of directors of EyeCool,” Dr. Thompson said. “While I have served on many industry medical advisory boards, I am thrilled to join EyeCool's board because this investigational product could have great utility and broad applicability in ophthalmology. Having acted as principal investigator on many FDA-monitored trials, I look forward to helping guide this product through to commercialization.”

EyeCool also announced the creation of a Medical Advisory Board (MAB). According to Cristos Ifantides, MD, MBA, Chief Medical Advisor, the MAB will help accelerate development and patient access to EyeCool’s investigational therapy for chronic ocular surface pain (COSP).

Anat Galor, MD, and Bonnie Henderson,MD, members of the existing Scientific Advisory Board, will transition to the newly formed MAB. Other experts that will be joining the MAB include: Sumit Garg, MD; Preeya Gupta, MD;  Francis Price, MD; William Trattler, MD; and William Wiley, MD.